Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer

12 de octubre de 2026 actualizado por: AbbVie

A Phase 1 First-in-Human, Open-Label Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-901 as a Monotherapy and in Combination in Adult Subjects With Ovarian Cancer

Ovarian cancer (OC) is a lethal disease. The purpose of this study is to assess the safety, pharmacokinetics and efficacy of ABBV901, alone or in combination with other anticancer drugs, in participants with ovarian cancer.

ABBV901 is an investigational drug for the treatment of ovarian cancer. This study has 6 parts where participants will receive ABBV-901, alone or in combination with other anticancer therapies. Around 285 participants will be enrolled in the study at approximately 45 sites around the world.

In part 1, participants will receive escalating doses of intravenous (IV) ABBV-901 alone. In part 2, participants will receive 1 of 3 doses of IV ABBV-901 alone to determine the optimized dose. In part 3, participants will receive escalating doses of IV ABBV-901 in combination with IV bevacizumab. In part 4, participants will receive recommended doses for expansion of IV ABBV-901 combination with IV bevacizumab. in Part 5, participants will receive escalating doses of IV ABBV-901 in combination with IV carboplatin and IV bevacizumab and in part 6, participants will receive recommended doses for expansion of IV ABBV-901 combination with IV carboplatin and IV bevacizumab. The total study duration will be approximately 3 years.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans.

Descripción general del estudio

Estado

Reclutamiento

Condiciones

Tipo de estudio

Intervencionista

Inscripción (Estimado)

285

Fase

  • Fase 1

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

    • New South Wales
      • Blacktown, New South Wales, Australia, 2148
        • Reclutamiento
        • Blacktown Hospital /ID# 282426
    • Victoria
      • Clayton, Victoria, Australia, 3168
        • Reclutamiento
        • Monash Health - Monash Medical Centre - Clayton /ID# 281468
      • Melbourne, Victoria, Australia, 3000
        • Reclutamiento
        • Peter MacCallum Cancer Centre. /ID# 281751
      • Barcelona, España, 08035
        • Reclutamiento
        • Hospital Universitari Vall d Hebron /ID# 280442
      • Madrid, España, 28040
        • Reclutamiento
        • Hospital Universitario Fundacion Jimenez Diaz /ID# 280440
      • Madrid, España, 28050
        • Reclutamiento
        • Hospital Universitario HM Sanchinarro /ID# 280439
    • Madrid
      • Majadahonda, Madrid, España, 28222
        • Reclutamiento
        • Hospital Universitario Puerta de Hierro - Majadahonda /ID# 280459
    • California
      • Duarte, California, Estados Unidos, 91010
        • Reclutamiento
        • City of Hope National Medical Center /ID# 281381
      • Irvine, California, Estados Unidos, 92618
        • Reclutamiento
        • City of Hope - Orange County Lennar Foundation Cancer Center /ID# 280914
    • Colorado
      • Denver, Colorado, Estados Unidos, 80218
        • Reclutamiento
        • Sarah Cannon Research Institute at HealthONE /ID# 278785
    • Illinois
      • Chicago, Illinois, Estados Unidos, 60637
        • Reclutamiento
        • University of Chicago Medical Center /ID# 278295
    • Nebraska
      • Omaha, Nebraska, Estados Unidos, 68198
        • Reclutamiento
        • University Of Nebraska Medical Center /ID# 281020
    • Texas
      • San Antonio, Texas, Estados Unidos, 78229
        • Reclutamiento
        • NEXT Oncology - San Antonio /ID# 278606
    • Utah
      • West Valley City, Utah, Estados Unidos, 84119
        • Reclutamiento
        • Start Mountain Region /ID# 278609
    • Virginia
      • Fairfax, Virginia, Estados Unidos, 22031
        • Reclutamiento
        • Next Virginia /ID# 278607
    • Pays de la Loire Region
      • Saint-Herblain, Pays de la Loire Region, Francia, 44805
        • Reclutamiento
        • Institut De Cancerologie De L'Ouest - Site Rene Gauducheau /ID# 280684
    • Rhone
      • Lyon, Rhone, Francia, 69373
        • Reclutamiento
        • Centre Leon Berard /ID# 280575
      • Haifa, Israel, 3109601
        • Reclutamiento
        • Rambam Health Care Campus /ID# 278418
      • Jerusalem, Israel, 91120
        • Reclutamiento
        • Hadassah Medical Center-Hebrew University /ID# 278420
    • Tel Aviv
      • Ramat Gan, Tel Aviv, Israel, 5265601
        • Reclutamiento
        • The Chaim Sheba Medical Center /ID# 278416
    • Chiba
      • Kashiwa-shi, Chiba, Japón, 277-8577
        • Reclutamiento
        • National Cancer Center Hospital East /ID# 278604
    • Saitama
      • Hidaka, Saitama, Japón, 350-1298
        • Reclutamiento
        • Saitama Medical University International Medical Center /ID# 278437
    • Shizuoka
      • Sunto-gun, Shizuoka, Japón, 411-8777
        • Reclutamiento
        • Shizuoka Cancer Center /ID# 278538
      • Lisbon, Portugal, 1649-035
        • Reclutamiento
        • Unidade Local de Saude de Santa Maria /ID# 280296
      • Porto, Portugal, 4200-072
        • Reclutamiento
        • Instituto Portugues de Oncologia do Porto Francisco Gentil /ID# 280293
      • Taipei, Taiwán, 112
        • Reclutamiento
        • Taipei Veterans General Hospital /ID# 281349
      • Taipei, Taiwán, 100
        • Reclutamiento
        • National Taiwan University Hospital /ID# 280701

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Diagnosis of an advanced or unresectable malignant high grade serous epithelial ovarian, fallopian tube, and primary peritoneal cancers (EOC), fallopian tube or primary peritoneal cancer by histology (World Health Organization [WHO] criteria).
  • Participants enrolled in backfill (Part 1) must provide consent to paired fresh biopsies which are pretreatment and on-treatment tumor biopsies from the same tumor lesion.

For Parts 1-4:

- Participants must be considered platinum resistant or platinum ineligible. Platinum resistant disease is defined as radiographic progression within 6 months (up to 182 days) after the last dose of the most recent platinum therapy).

For Parts 5-6:

- Participants will have platinum-sensitive disease defined as radiographic progression > 6 months from last dose of platinum-based chemotherapy. Note: Progression should be calculated from the date of the last administered dose of platinum therapy to the date of the radiographic imaging showing progression.

Exclusion Criteria:

  • Ovarian Cancer (OC) with histologies other than high grade serous OC including endometrioid, low grade, mucinous, carcinosarcoma or sarcomatous histology, mixed tumors or low grade/borderline ovarian tumor.
  • Participants with platinum refractory disease.
  • Prior therapy with an antibody-drug conjugate containing a topoisomerase inhibitor.
  • Prior history of Grade >= 2 interstitial lung disease (ILD) or pneumonitis.
  • Prior history of Grade 2 >= 2 ILD or pneumonitis or any evidence of active ILD or pneumonitis on Screening chest computed tomography (CT) scan.

For Parts 3-6:

  • History of Grade 3/4 adverse events that, in the opinion of the investigator, are attributed to bevacizumab.
  • History of clinically significant cardiac disease including CHF Class II or higher NYHA; active coronary artery disease, MI within 6 months prior to study entry; unevaluated new onset angina within 3 months or unstable angina (angina symptoms at rest) or cardiac arrhythmias requiring antiarrhythmic therapy (beta blockers or digoxin are permitted).
  • Echocardiogram with ejection fraction <= 50% and no other clinically significant cardiac abnormalities that in the opinion of the investigator, would increase the participants susceptibility to cardiac toxicity.

For Parts 5-6:

- Participants who had prior allergic reaction to platinum containing compound.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación Secuencial
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Part 1: ABBV-901 Dose Escalation

Participants will receive escalating doses of ABBV-901 alone, as part of the approximately 3 year study duration.

Intravenous (IV)

Experimental: Part 2: ABBV-901 Optimization Dose A

Participants will receive ABBV-901 dose A alone, as part of the approximately 3 year study duration.

Intravenous (IV)

Experimental: Part 2: ABBV-901 Optimization Dose B

Participants will receive ABBV-901 dose B alone, as part of the approximately 3 year study duration.

Intravenous (IV)

Experimental: Part 2: ABBV-901 Optimization Dose C

Participants will receive ABBV-901 dose C alone, as part of the approximately 3 year study duration.

Intravenous (IV)

Experimental: Part 3: ABBV-901 + Bevacizumab Escalation

Participants will receive escalating doses of ABBV-901 in combination Bevacizumab, as part of the approximately 3 year study duration.

Intravenous (IV)

Intravenous (IV)

Experimental: Part 4: ABBV-901 + Bevacizumab Expansion

Participants will receive the recommended doses for expansion doses of ABBV-901 in combination Bevacizumab, as part of the approximately 3 year study duration.

Intravenous (IV)

Intravenous (IV)

Experimental: Part 5: ABBV-901 + Carboplatin + Bevacizumab Escalation

Participants will receive escalating doses of ABBV-901 in combination with Carboplatin & Bevacizumab, as part of the approximately 3 year study duration.

Intravenous (IV)

Intravenous (IV)

Intravenous (IV)

Experimental: Part 6: ABBV-901 + Carboplatin + Bevacizumab Expansion

Participants will receive the recommended doses for expansion doses of ABBV-901 in combination with Carboplatin & Bevacizumab, as part of the approximately 3 year study duration.

Intravenous (IV)

Intravenous (IV)

Intravenous (IV)

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Number of Participants with Adverse Events (AE)
Periodo de tiempo: Up to Approximately 3 Years

An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have a causal relationship with this treatment.

Up to Approximately 3 Years
Overall Response (as assessed by the investigator)
Periodo de tiempo: Up to Approximately 3 Years

Overall response is defined as participants achieving confirmed complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as assessed by the investigator.

Up to Approximately 3 Years

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Overall Response (as assessed by independent central review)
Periodo de tiempo: Up to Approximately 3 Years

Overall response is defined as participants achieving confirmed complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as assessed by independent central review (ICR).

Up to Approximately 3 Years
Duration of Response (DOR)
Periodo de tiempo: Up to Approximately 3 Years

DOR is defined for participants achieving a confirmed PR or better as the time from the initial response of PR (or better) per investigator review according to RECIST Version 1.1 criteria to disease progression or death of any cause, whichever occurs earlier.

Up to Approximately 3 Years
Progression-free survival (PFS)
Periodo de tiempo: Up to Approximately 3 Years

PFS is defined as time from first study treatment to a documented disease progression according to RECIST Version 1.1 (or other assessment criteria), as determined by the investigator, or death due to any cause, whichever occurs earlier.

Up to Approximately 3 Years
Overall Survival (OS)
Periodo de tiempo: Up to Approximately 3 Years

OS is defined as time from first study treatment to death due to any cause.

Up to Approximately 3 Years
Disease Control Rate
Periodo de tiempo: Up to Approximately 3 Years

Disease Control Rate is defined as the percentage of participants with best overall response (BOR) of stable disease (SD), PR or better per investigator review according to RECIST version 1.1 criteria.

Up to Approximately 3 Years

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Director de estudio: ABBVIE INC., AbbVie

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

27 de noviembre de 2025

Finalización primaria (Estimado)

1 de diciembre de 2028

Finalización del estudio (Estimado)

1 de enero de 2029

Fechas de registro del estudio

Enviado por primera vez

2 de diciembre de 2025

Primero enviado que cumplió con los criterios de control de calidad

2 de diciembre de 2025

Publicado por primera vez (Actual)

12 de diciembre de 2025

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

13 de octubre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

12 de octubre de 2026

Última verificación

1 de octubre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

producto fabricado y exportado desde los EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir